What is the half-life of Femara (letrozole) and when does it peak in the body?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Femara (Letrozole) Pharmacokinetics

Femara has a terminal elimination half-life of approximately 2 days (about 40-48 hours), and plasma concentrations peak within 2 hours after oral administration. 1

Peak Plasma Concentration (Tmax)

  • Letrozole reaches peak plasma levels within 2 hours after oral administration 1
  • This rapid absorption occurs regardless of food intake, as absorption is not affected by food 1
  • The drug is rapidly and completely absorbed from the gastrointestinal tract 1

Half-Life Details

  • The terminal elimination half-life is approximately 2 days (ranging from 40-48 hours in various studies) 1, 2
  • More specifically, studies report the half-life as 2-4 days depending on the patient population 2
  • After a single dose, the terminal half-life is approximately 41-48 hours 2

Time to Steady State

  • Steady-state plasma concentrations are reached in 2 to 6 weeks with daily 2.5 mg dosing 1
  • Some studies report steady state is achieved after approximately 60 days of continuous daily dosing 2
  • At steady state, plasma concentrations are 1.5 to 2 times higher than predicted from single-dose measurements, indicating slight non-linearity in pharmacokinetics 1

Important Clinical Considerations

  • The long half-life means maximal estrogen suppression is achieved within 2-3 days of treatment initiation and is maintained throughout treatment 1, 3
  • Despite the 2-day half-life, continuous accumulation does not occur once steady state is reached 1
  • Age does not significantly affect letrozole pharmacokinetics in adults ranging from 35 to over 80 years 1
  • Approximately 90% of letrozole is weakly protein-bound with a large volume of distribution (approximately 1.9 L/kg) 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.